| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.69 [0.25, 1.89] | | < 1 | | 0% | 1 study (1/-) | 76.5 % | NA | not evaluable | | crucial | - |
| events or deaths (EFS) | 0.76 [0.40, 1.44] | | < 1 | | 0% | 1 study (1/-) | 79.9 % | NA | not evaluable | | non important | - |
| pCR | 1.95 [1.26, 3.01] | | > 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.49 [0.02, 14.69] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.10 [0.71, 1.72] | | < 1 | | 0% | 1 study (1/-) | 33.2 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.02 [0.06, 16.42] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.18 [0.70, 2.01] | | < 1 | | 0% | 1 study (1/-) | 26.7 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 2.00 [1.20, 3.36] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.58 [0.91, 2.75] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.98 [0.14, 7.05] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.15 [0.74, 1.77] | | < 1 | | 0% | 1 study (1/-) | 26.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 0.51 [0.02, 15.24] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.06, 16.42] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.02 [0.32, 3.23] | | < 1 | | 0% | 1 study (1/-) | 48.7 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.51 [0.02, 15.24] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 1.21 [0.54, 2.69] | | < 1 | | 0% | 1 study (1/-) | 32.4 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 1.54 [0.25, 9.32] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.51 [0.02, 15.24] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 4.15 [0.46, 37.53] | | < 1 | | 0% | 1 study (1/-) | 10.4 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dyspepsia AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.02 [0.14, 7.32] | | < 1 | | 0% | 1 study (1/-) | 49.3 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.23 [0.37, 4.11] | | < 1 | | 0% | 1 study (1/-) | 36.8 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 1.25 [0.61, 2.57] | | < 1 | | 0% | 1 study (1/-) | 27.3 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.51 [0.02, 15.24] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.84 [0.35, 2.00] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 2.44 [0.62, 9.59] | | < 1 | | 0% | 1 study (1/-) | 10.2 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 0.91 [0.36, 2.30] | | < 1 | | 0% | 1 study (1/-) | 57.7 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 1.02 [0.06, 16.42] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Lacrimation increased AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 1.86 [0.76, 4.55] | | < 1 | | 0% | 1 study (1/-) | 8.9 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.28 [0.06, 1.38] | | < 1 | | 0% | 1 study (1/-) | 94.0 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 1.10 [0.65, 1.84] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Oropharyngeal pain AE (grade 3-4) | 2.04 [0.07, 61.32] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 1.02 [0.02, 51.63] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.40 [0.08, 2.09] | | < 1 | | 0% | 1 study (1/-) | 86.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.51 [0.02, 15.24] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy AE (grade 3-4) | 1.28 [0.34, 4.86] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.25 [0.03, 2.26] | | < 1 | | 0% | 1 study (1/-) | 89.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 4.11 [0.18, 91.86] | | < 1 | | 0% | 1 study (1/-) | 18.9 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 4.15 [0.46, 37.53] | | < 1 | | 0% | 1 study (1/-) | 10.4 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 6.20 [0.31, 124.85] | | < 1 | | 0% | 1 study (1/-) | 11.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 2.05 [0.18, 22.82] | | < 1 | | 0% | 1 study (1/-) | 28.1 % | NA | not evaluable | | non important | - |
